Free Trial

Moody Aldrich Partners LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

AnaptysBio logo with Medical background

Moody Aldrich Partners LLC acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 83,224 shares of the biotechnology company's stock, valued at approximately $1,547,000. Moody Aldrich Partners LLC owned 0.27% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. HighMark Wealth Management LLC purchased a new stake in shares of AnaptysBio during the first quarter valued at approximately $1,710,000. Farther Finance Advisors LLC raised its stake in shares of AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,858 shares during the period. Rhumbline Advisers raised its stake in shares of AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock valued at $574,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC purchased a new stake in shares of AnaptysBio during the first quarter valued at approximately $113,000. Finally, Wellington Management Group LLP raised its stake in shares of AnaptysBio by 0.8% during the fourth quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock valued at $880,000 after purchasing an additional 528 shares during the period.

Insider Buying and Selling

In other news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the transaction, the director owned 4,965 shares of the company's stock, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 33.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ANAB. Guggenheim reissued a "buy" rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and raised their price target for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Finally, Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 29th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $42.38.

Check Out Our Latest Stock Analysis on AnaptysBio

AnaptysBio Trading Down 1.3%

AnaptysBio stock traded down $0.30 during mid-day trading on Monday, reaching $23.45. The company's stock had a trading volume of 448,281 shares, compared to its average volume of 642,332. The firm has a market cap of $688.96 million, a price-to-earnings ratio of -4.84 and a beta of -0.27. The business has a 50 day moving average price of $21.93 and a 200-day moving average price of $18.64. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. On average, equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a stock repurchase plan on Monday, March 24th that permits the company to buyback $75.00 million in shares. This buyback authorization permits the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board believes its stock is undervalued.

AnaptysBio Profile

(Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

See Also

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Should You Invest $1,000 in AnaptysBio Right Now?

Before you consider AnaptysBio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.

While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines